We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about atrial fibrillation and heart failure with reduced and preserved ejection fraction.
Questions:
- What is the prevalence of atrial fibrillation (AF) in patients with heart failure (HF) and reduced (HFrEF) and preserved (HFpEF) ejection fraction? (0.13)
- What is the impact of AF on prognosis in patients with HFpEF and HFrEF? (1.14)
- What factors should be considered when prescribing therapies for patients with AF and HF? (2.12)
- How does treatment of AF impact HFpEF outcomes? (3.07)
Speaker disclosures: Professor Hugh Calkins is a consultant and/or has received honoraria from Atricure, Biosense Webster, Abbott, Medtronic and Ablacon.
Commissioned, edited and funded by Touch Medical Media.
Filmed during a remote video call with Professor Hugh Calkins as a highlight of the AF Symposium, January 2021.